GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » E10

Marizyme (Marizyme) E10 : $-5.30 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Marizyme E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Marizyme's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.050. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-5.30 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -2.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Marizyme was -2.00% per year. The lowest was -3.80% per year. And the median was -2.90% per year.

As of today (2024-06-09), Marizyme's current stock price is $0.093. Marizyme's E10 for the quarter that ended in Mar. 2024 was $-5.30. Marizyme's Shiller PE Ratio of today is .


Marizyme E10 Historical Data

The historical data trend for Marizyme's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marizyme E10 Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.70 -6.78 -7.28 -7.50 -7.20

Marizyme Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.72 -7.66 -7.61 -7.20 -5.30

Competitive Comparison of Marizyme's E10

For the Biotechnology subindustry, Marizyme's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marizyme's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marizyme's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Marizyme's Shiller PE Ratio falls into.



Marizyme E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Marizyme's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.05/131.7762*131.7762
=-0.050

Current CPI (Mar. 2024) = 131.7762.

Marizyme Quarterly Data

per share eps CPI Adj_EPS
201109 -2.233 95.727 -3.074
201112 -1.160 95.213 -1.605
201203 -11.861 96.783 -16.150
201206 -0.870 96.819 -1.184
201209 -0.397 97.633 -0.536
201212 0.806 96.871 1.096
201303 -1.296 98.209 -1.739
201306 -0.188 98.518 -0.251
201309 -1.082 98.790 -1.443
201312 0.229 98.326 0.307
201412 -9.367 99.070 -12.459
201512 -8.207 99.792 -10.837
201612 -0.783 101.863 -1.013
201709 0.036 104.136 0.046
201712 -0.578 104.011 -0.732
201803 -0.040 105.290 -0.050
201806 -0.060 106.317 -0.074
201809 -0.070 106.507 -0.087
201812 -0.003 105.998 -0.004
201903 -0.003 107.251 -0.004
201906 -0.010 108.070 -0.012
201909 -0.030 108.329 -0.036
201912 -0.010 108.420 -0.012
202003 -0.020 108.902 -0.024
202006 -0.020 108.767 -0.024
202009 -0.070 109.815 -0.084
202012 -0.090 109.897 -0.108
202103 -0.080 111.754 -0.094
202106 -0.050 114.631 -0.057
202109 -0.050 115.734 -0.057
202112 -0.160 117.630 -0.179
202203 -0.150 121.301 -0.163
202206 -0.170 125.017 -0.179
202209 -0.040 125.227 -0.042
202212 -0.580 125.222 -0.610
202303 -0.060 127.348 -0.062
202306 -0.480 128.729 -0.491
202309 -0.710 129.860 -0.720
202312 -0.160 129.419 -0.163
202403 -0.050 131.776 -0.050

Add all the adjusted EPS together and divide 10 will get our e10.


Marizyme  (OTCPK:MRZM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Marizyme E10 Related Terms

Thank you for viewing the detailed overview of Marizyme's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Marizyme (Marizyme) Business Description

Traded in Other Exchanges
N/A
Address
555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Executives
Braeden Lichti 10 percent owner 650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7
Nilesh Umedbhai Patel director 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Michael R Stewart director 5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044
Harrison Ross officer: Vice President of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Georgiy Kovalyov officer: Chief Financial Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
David Barthel director, officer: Chief Executive Officer 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Bradley Richmond officer: Acting VP of Finance 555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Julie B. Kampf director 14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410
Vithalbhai D Dhaduk director FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512
Neil J Campbell director, officer: Chief Executive Officer 225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Very Donald Leroy Jr officer: Executive Vice President 4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739
William Hearl director 448 SALK CIRCLE, GAITHERSBERG MD 20878
Bruce Harmon officer: Chief Financial Officer 316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Catherine J. Pachuk officer: Chief Science Officer 1033 N. JEAGA DR, JUPITER FL 33458
Satishchandran Chandrasekhar officer: Chief Operating Officer 167 CARMELA COURT, JUPITER FL 33478